Kaleido Biosciences (KLDO) Income Statement
Kaleido Biosciences Income Statement
Last quarter (Q4 2021), Kaleido Biosciences's total revenue was $492.00K, an increase of 102.47% from the same quarter last year. In Q4, Kaleido Biosciences's net income was $-21.12M. See Kaleido Biosciences’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 |
|---|---|---|---|---|---|
| $ 1.10M | $ 975.00K | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -1.25M | $ -54.99M | $ -1.32M | $ 0.00 | $ 0.00 | |
| $ 86.41M | $ 23.88M | $ 86.66M | $ 60.68M | $ 27.03M | |
| Depreciation and Amortization | $ 2.36M | $ 1.82M | $ 1.32M | $ 792.00K | $ 316.00K |
| $ -85.09M | $ -77.00M | $ -84.04M | $ -59.03M | $ -26.70M | |
| $ -87.67M | $ -78.87M | $ -86.66M | $ -60.68M | $ -27.03M | |
| $ -2.62M | $ -2.75M | $ 329.00K | $ -1.06M | $ -529.00K | |
| $ -90.29M | $ -81.62M | $ -86.33M | $ -61.74M | $ -27.56M | |
| $ -90.29M | $ -81.62M | $ -85.01M | $ -61.74M | $ -27.56M | |
| Per Share Metrics | |||||
| Basic EPS | $ -2.16 | $ -2.44 | $ -3.31 | $ -2.10 | $ -1.23 |
| Diluted EPS | $ -2.16 | $ -2.44 | $ -3.31 | $ -2.10 | $ -1.23 |
| Weighted Average Shares Outstanding | 41.86M | 33.45M | 25.70M | 29.39M | 22.42M |
| Weighted Average Shares Outstanding (Diluted) | 41.86M | 33.45M | 25.70M | 29.39M | 22.42M |
Currency in USD
